NRx Pharmaceuticals (NRXP) Stock Price, News & Analysis

Company Overview

NRx Pharmaceuticals, Inc., a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders, including suicidal depression, post-traumatic stress disorder, and chronic pain. Its products include NRX-101 (D-cycloserine/Lurasidone), an oral, fixed dosed combination of D-cycloserine and lurasidone that earned food and drug administration-designated breakthrough therapy for suicidal treatment-resistant bipolar depression; and NRX-100 (ketamine), which has been awarded FDA fast track designation for the treatment of severe bipolar depression with acute suicidal ideation and behavior. The company has a partnership with Alvogen Inc. and Lotus Pharmaceutical Company; development and manufacturing agreement with Nephron Pharmaceuticals, Inc. and Alcami; license agreement with Apkarian Technologies; development and license agreement with Glytech; license agreement with Sarah Herzog Memorial Hospital. The company was founded in 2015 and is based in Wilmington, Delaware.

Key Stats

• Today's Range: $3.60 to $4.28
• 50-Day Range: $1.16 to $5.10
• 52-Week Range: $1.10 to $7.33
• Volume: 1.06 million shs
• Average Volume: 2.73 million shs
• Market Capitalization: $48.48 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $31.67
• Consensus Rating: Buy

NRx Pharmaceuticals Stock Analysis - MarketRank™

NRx Pharmaceuticals scored higher than 57% of companies evaluated by MarketBeat, and ranked 460th out of 944 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.6 / 5
• Analyst Rating: Buy

Consensus Rating

NRx Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.25, and is based on 3 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

NRx Pharmaceuticals has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for NRx Pharmaceuticals are expected to grow in the coming year, from ($1.75) to ($0.08) per share.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

6.99% of the float of NRx Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

NRx Pharmaceuticals has a short interest ratio ("days to cover") of 0.7, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in NRx Pharmaceuticals has recently increased by 7.20%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

NRx Pharmaceuticals does not currently pay a dividend.

Dividend Growth

NRx Pharmaceuticals does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

6.99% of the float of NRx Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

NRx Pharmaceuticals has a short interest ratio ("days to cover") of 0.7, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in NRx Pharmaceuticals has recently increased by 7.20%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 2.2 / 5
• News Sentiment: -0.02

News Sentiment

NRx Pharmaceuticals has a news sentiment score of -0.02. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.49 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 4 news articles for NRx Pharmaceuticals this week, compared to 2 articles on an average week.

Search Interest

19 people have searched for NRXP on MarketBeat in the last 30 days. This is an increase of 375% compared to the previous 30 days.

MarketBeat Follows

6 people have added NRx Pharmaceuticals to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: Acquiring Shares

Insider Buying vs. Insider Selling

In the past three months, NRx Pharmaceuticals insiders have bought more of their company's stock than they have sold. Specifically, they have bought $46,800.00 in company stock and sold $0.00 in company stock.

Percentage Held by Insiders

19.00% of the stock of NRx Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Only 4.27% of the stock of NRx Pharmaceuticals is held by institutions.

NRXP Stock Analysis - Frequently Asked Questions

How have NRXP shares performed this year?

NRx Pharmaceuticals' stock was trading at $2.20 on January 1st, 2025. Since then, NRXP stock has increased by 82.3% and is now trading at $4.01.
View the best growth stocks for 2025 here.

When did NRx Pharmaceuticals' stock split?

NRx Pharmaceuticals shares reverse split on Tuesday, April 2nd 2024. The 1-10 reverse split was announced on Tuesday, April 2nd 2024. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, April 2nd 2024. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

How do I buy shares of NRx Pharmaceuticals?

Shares of NRXP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of NRx Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that NRx Pharmaceuticals investors own include NVIDIA (NVDA), Broadcom (AVGO), Arista Networks (ANET), Adobe (ADBE), Meta Platforms (META), General Electric (GE) and Disc Medicine (IRON).

Company Calendar

• Today: 1/21/2025
• Next Earnings (Estimated): 3/26/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:NRXP
• CUSIP: N/A
• CIK: 1719406
• Web: www.bigrockpartners.com
• Phone: (484) 254-6134
• Fax: N/A
• Employees: 2
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $31.67
• High Stock Price Target: $45.00
• Low Stock Price Target: $19.00
• Potential Upside/Downside: +689.7%
• Consensus Rating: Buy
• Rating Score (0-4): 3.25
• Research Coverage: 4 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($2.14)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-30,150,000.00
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: -449.16%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.20
• Quick Ratio: 0.20

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($1.38) per share
• Price / Book: -2.91

Miscellaneous

• Outstanding Shares: 12,090,000
• Free Float: 9,796,000
• Market Cap: $48.48 million
• Optionable: Optionable
• Beta: 1.08